The Centers for Medicare & Medicaid Services this week released for comment a proposal that Medicare cover diagnostic laboratory tests that use Next Generation Sequencing for patients with a breast or ovarian cancer that may be inherited. The test used must be approved by the Food and Drug Administration, ordered by a treating physician for a patient not previously tested using NGS, and performed in a laboratory certified under the Clinical Laboratory Improvement Amendments program, among other requirements. Under the proposal, Medicare administrative contractors also could decide to cover the tests for patients with other cancers that may be inherited.

Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Centers for Medicare & Medicaid Services released a proposed rule Oct. 16 seeking to codify regulations that will improve the accuracy of Medicare…
Headline
The Centers for Medicare & Medicaid Services announced that it will exercise enforcement discretion for inpatient rehabilitation facility admissions from…
Headline
The Centers for Medicare & Medicaid Services has released 2027 Medicare Advantage plan information, including star ratings, through the Medicare Plan…
Headline
The AHA provided comments to the Medicare Payment Advisory Commission Oct. 2 on a discussion from the commission’s September meeting on its examination of…